The Influence of Imatinib Mesylate (STI571) used alone or in Combination with Purine Nucleoside Analogues on the Normal and Chronic Myelogenous Leukaemia Progenitor Cells In Vitro

References

• Melo J. V. “The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype”. Blood 1996; 88: 2375–2384
   PubMed Web of Science ®Google Scholar
• Deininger M. W.N., Goldman J. M., Lydon N., Melo J. V. “The tyrosine kinase inhibitor CGP57I148B selectively inhibits the growth of BCR-ABL-positive cells”. Blood 1997; 90: 3691–3698
   PubMed Web of Science ®Google Scholar
• Druker B. J., Talpaz M., Resta D. J., Peng B., Buchdunger E., Ford J. M., Lydon N. B., Kantarijan H., Capdeville R., Ohno-Jones S., Sawyers C. L. “Efficacy and safty od a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia”. N. Engl. J. Med 2001; 344: 1031–1037
   PubMed Web of Science ®Google Scholar
• Druker B. J., Sawyers C. L., Kantarijan H., Resta D. J., Reese S. F., Ford J. M., Cardeville R., Talpaz M. “Activity of specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome”. N. Engl. J. Med 2001; 344: 1038–1042
   PubMed Web of Science ®Google Scholar
• Sawyers C. L., Hochhaus A., Feldman E., Goldman J. M., Miller C. B., Ottmann O. G., Schiffer C. A., Talpaz M., Guilhot E., Deininger M. W.N., Fischer T., O'Brien S. G., Stone R. M., Gambacorti-Passerini C. B., Russel N. H., Reiffers J. J., Shea T. C., Chapuis B., Coutre S., Tura S., Morra E., Larson R. A., Saven A., Peschel C., Gratwohl A., Mandelli F., Ben-Am M., Gathmann I., Capdeville R., Paquette R. L., Druker B. J. “Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crises: results of a phase II study”. Blood 2002; 99: 3530–3539
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Cortes J., O'Brien S., Giles F. J., Albitar M., Rios M. B., Shan J., Faderl S., Garcia-Manero G., Thomas D. A., Resta D., Talpaz M. “Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase”. Blood 2002; 99: 3547–3553
   PubMed Web of Science ®Google Scholar
• Hallek M., Schmitt B., Wilhelm M., Busch R., Krober A., Fostitsch H. P., Sezer O., Herold M., Knauf W., Wendtner C. M., Kuse R., Freund M., Franke A., Schriever F., Nerl C., Dohner H., Thiel E., Hiddemann W., Brittinger G., Emmerich B. “Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group”. Br. J. Haematol 2001; 114: 342–348
   PubMed Web of Science ®Google Scholar
• Robak T., Blonski J. Z., Kasznicki M., Blasinska-Morawiec M., Krykowski E., Dmoszynska A., Mrugala-Spiewak H., Skotnicki A. B., Nowak W., Konopka L., Ceglarek B., Maj S., Dwilewicz-Trojaczek J., Hellmann A., Urasinski I., Zdziarska B., Kotlarek-Haus S., Potoczek S., Grieb P. “Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial”. Blood 2000; 96: 2723–2729
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Magagnoli M., Bendandi M., Tani M., Stefoni V., Cellini C., Poggi S., Piccioli M., Pileri S., Tura S. “Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyaden-sine”. Haematologira 2000; 85: 922–925
   PubMed Web of Science ®Google Scholar
• Gordon M. S., Young M. L., Tallman M. S., Cripe L. D., Bennett J. M., Paietta E., Longo W., Gerad H., Mazza J., Rowe J. M. “Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG). E5995”. Leuk. Res 2000; 24: 871–875
   PubMed Web of Science ®Google Scholar
• Martinelli G., Zinzani P. L., Farabegoli P. “Purine analogues (Fludarabine and 2-chlorodeoxyadenosine) as apoptosis-inducing drugs in CML therapy”. Hematologica 1996; 81: 286–287
   PubMed Web of Science ®Google Scholar
• Cortes J., Kantarijan H., Talpaz M., O'Brian S., Koller C., Keating M. “Treatment of chronic myelogenous leukemia with nucleoside analogues deoxycoformycin and fludarabine”. Leukemia 1997; 11: 788–791
   PubMed Web of Science ®Google Scholar
• Saven A., Piro L. D., Lemon R. H., Figueroa M. L., Kosty M., Ellison D. J., Beutler E. “Complete hematologic remission in chronic phase, Philadelphia chromosome-positive. chronic myelogenous leukemia after 2-chlorodeoxy-adenosine”. Cancer 1994; 73: 2953–2963
   PubMed Web of Science ®Google Scholar
• Robak T., Korycka A. “The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with interferon α (IFNα) or interferon γ (IFN-γ) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in cultures in vitro“. Leuk. Lymphoma 1996; 21: 161–168
   PubMed Web of Science ®Google Scholar
• Korycka A., Robak T. “The influence of recombinant human tumor necrosis factor α and its muteins used alone or in combination with 2-chlorodeoxyadenosine on normal and leukemic hematopoiesis in vitro“. Leuk. Res 1997; 21: 857–865
   PubMed Web of Science ®Google Scholar
• Lech-Maranda E., Korycka A., Robak T. “Influence of gemcytabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro“. Eur, J. Haematol 2000; 65: 317–321
   PubMed Web of Science ®Google Scholar
• Thiesing J. T., Ohno-Jones S., Kolibaba S., Druker B. J. “Efficacy of STI571, an tyrosine kinase inhibitor, in conjunction with other antileukemic agent against Bcr-Abl-positive cells”. Blood 2000; 96: 3195–3199
   PubMed Web of Science ®Google Scholar
• Marley S. B., Davidson R. J., Lewis J. L., Nguyen D. X., Eades A., Parker S., Goldman J. M., Gordon M. Y. “Progenitor cells from patients with advanced phase chronic myeloid leukemia responded to STI571 in vitro and in vivo“. Leuk. Res 2001; 25: 997–1002
   PubMed Web of Science ®Google Scholar
• Kazimierczuk Z., Vilpo J., Hildebrand Z., Wright G. “Synthesis and cytotoxicity of deoxyadenosine analogues: isomer distribution in the sodium salt glycosylation of 2,6-disubstitutes purines”. J. Med. Chem 1990; 33: 1683–1687
   PubMed Web of Science ®Google Scholar
• Iscove N. N., Sieber F., Winterhalter K. H. “Erythroid colony formation in culture of mouse and human bone marrow. Analysis of the requirement chromatography on agarose-cancana-valin A”. Am. J. Cell Physiol 1974; 83: 309–320
   Web of Science ®Google Scholar
• Tosi P., Visani G., Ottavina E., Manfroi S., Zinzani P. L., Tura S. “Fludarabine +Ara-C +G-CSF: Cytotoxic effect and induction of apaptosis on fresh acute myeloid leukemia cells”. Leukemia 1994; 8: 2076–2082
   PubMed Web of Science ®Google Scholar
• Korycka A., Robak T. “Amifostine and 2-CdA: a novel purging strategy in CML autografting”. Eur. J. Haematol 2000; 64: 347–349
   PubMed Web of Science ®Google Scholar
• Kristensen J., Nygren P., Liliemark J., Fridborg H., Killander A., Simonsson B., Oberg G., Larsson R. “Interactions between cladribine (2-chlorodeoxy-adenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia”. Leukemia 1994; 8: 1712–1717
   PubMed Web of Science ®Google Scholar
• Talpaz M., Silver R. Y., Druker B. J., Goldman J. M., Gambacorti-Passerini C., Guilhot E., Schiffer C. A., Fischer T., Deininger M. W.N., Lennard A. L., Hochhaus A., Ottmann O. G., Gratwohl A., Baccarani M., Stone R., Tura S., Mahon M. X., Fernandes-Reese S., Gathmann I., Capdeville R., Kantarjian H. M., Sawyers C. L. “Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study”. Blood 2002; 99: 1928–1937
   PubMed Web of Science ®Google Scholar
• Marley S. B., Deininger M. W.N., Davidson R. J., Goldman J. M., Gordon M. Y. “The tyrosine kinase inhibitor STI571, like interferon alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia”. Exp. Hematol 2000; 28: 551–557
   PubMed Web of Science ®Google Scholar
• Graham S. M., Jorgensen H. G., Allan E., Pearson C., Alcorn M. J., Richmond L., Holyoake T. “Primitive, quiescent. Philadelphia-positive stem cells from patients with chronic myeloid leukemia are intensive to STI57I in vitro“. Blood 2002; 99: 319–325
   PubMed Web of Science ®Google Scholar
• Holtz M. S., Slovak M. L., Zhang F., Sawyers C. L., Forman S. J., Bhatia R. “Imanitib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation”. Blood 2002; 99: 3792–3800
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Melo J. V. “Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia”. N. Engl. J. Med 2001; 344: 1084–1086
   PubMed Web of Science ®Google Scholar
• Chou T. B., Talalay P. “Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs or enzyme inhibitors”. Adv. Enzyme Regal 1984; 22: 27–55
   PubMedGoogle Scholar
• Fruehauf S., Topaly J., Laut's S., Zeller W. J., Ho A. D. “STI571-based combination therapy of chronic myelogenous leukemia: preclinical data”. Blood 2001; 98: 257b
   PubMed Web of Science ®Google Scholar
• Kano Y., Akutsu M., Tsunoda S., Mano H., Sato Y., Honma Y., Furukawa Y. “In vitro cytotoxic effect of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents”. Blood 2001; 97: 1999–2007
   PubMed Web of Science ®Google Scholar
• Marley S. B., Davidson J., Goldman J. M., Gordon M. Y. “Effect of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia”. Br. J. Haematol 2002; 116: 162–165
   PubMed Web of Science ®Google Scholar
• Topaly J., Zeller W. J., Fruehauf S. “Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells”. Leukemia 2001; 15: 342–347
   PubMed Web of Science ®Google Scholar
• Topaly J., Zeller W. J., Fruehauf S. “Combination therapy with Imatinib mesylate (STI571):synopsis of in vitro studies”. Br. J. Haematol 2002; 119: 3–14
   PubMed Web of Science ®Google Scholar
• Scappini B., Onida F., Kantarjian H. M., Dong L., Verstovsek S., Keating M. J., Beran M. “In vitro effect of STI571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells”. Cancer 2002; 94: 2653–2662
   PubMed Web of Science ®Google Scholar
• Robak T. “Purine nucleoside analogues in the treatment of myeloid leukemias”. Leuk. Lymphoma 2003; 44: 391–409
   PubMed Web of Science ®Google Scholar